Suppr超能文献

大鼠和人脑中[123I]S(-)碘苯甲酰胺([123I]IBZM)的体外和体内D2-多巴胺受体结合情况

In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.

作者信息

Verhoeff N P, Bobeldijk M, Feenstra M G, Boer G J, Maas M A, Erdtsieck-Ernste E, de Bruin K, van Royen E A

机构信息

Academic Medical Centre, Department of Nuclear Medicine, Amsterdam, The Netherlands.

出版信息

Int J Rad Appl Instrum B. 1991;18(8):837-46. doi: 10.1016/0883-2897(91)90091-x.

Abstract

As a promising dopamine D2-receptor imaging agent for single photon emission computerized tomography (SPECT), 123I-(-)-2-hydroxy-3-iodo-6-methoxy-N [(1-ethyl-2-pyrrolidinyl)methyl]benzamide ([123I]IBZM) has recently been synthesized in a modified way along with its precursor, S(-)BZM, and the stereoisomer R(+)BZM. The present study applied this new product to investigate in vitro and in vivo D2-receptor binding in rat brain and in postmortem human brain. In vitro saturation binding curves with [123I]IBZM for rat crude striatal membrane preparations yielded an affinity constant (Kd) of 0.28 nM confirming data in the literature. Displacement curves revealed an order of increasing potency as follows: R(+)BZM less than S(-)sulpiride = less than S(-)BZM less than S(-)IBZM. A similar order was obtained when [3H]spiperone was used as ligand. For human putamen and caudate nucleus membranes slightly higher Kd values (0.49 nM) were obtained. Rank order of displacing potency for the various drugs was similar to that found in the rat preparations. In vivo uptake of [123I]IBZM in rat brain following injection of 50 microCi (12-16 pmol) in the tail vein revealed an increase in the striatum-to-cerebellum ratio from 1.5 at 5 min to 6.9 at 2 h. The olfactory tubercle-to-cerebellum ratio was also raised from 1.6 to 3.3. Other brain regions tested failed to show statistically significant enhancements. Coinjection of 40 nmol S(-)IBZM, 4 mumol S(-)BZM or 200 nmol haloperidol displaced [123I]IBMZ when tested at 90 min. The use of 4 mumol R(+)BZM resulted in minor displacement only, demonstrating that stereospecificity of the displacement was present in vivo and in vitro. Displacements were also observed in substantia nigra and pons-medulla oblongata, but not in hippocampus or frontal and occipital cortex. The data provide the required background needed in order to initiate in vivo binding studies for D2-receptors in basal ganglia of human patients using [123I]IBZM in SPECT analyses.

摘要

作为一种用于单光子发射计算机断层扫描(SPECT)的有前景的多巴胺D2受体显像剂,123I-(-)-2-羟基-3-碘-6-甲氧基-N-[(1-乙基-2-吡咯烷基)甲基]苯甲酰胺([123I]IBZM)及其前体S(-)BZM和立体异构体R(+)BZM最近已通过改良方法合成。本研究应用该新产品对大鼠脑和人死后脑组织进行体外和体内D2受体结合研究。用[123I]IBZM对大鼠纹状体粗膜制剂进行体外饱和结合曲线测定,得到的亲和常数(Kd)为0.28 nM,证实了文献中的数据。竞争曲线显示效价增加顺序如下:R(+)BZM<S(-)舒必利 = <S(-)BZM<S(-)IBZM。当使用[3H]螺哌隆作为配体时,得到了类似的顺序。对于人壳核和尾状核膜,获得了略高的Kd值(0.49 nM)。各种药物的竞争效价顺序与在大鼠制剂中发现的相似。尾静脉注射50微居里(12 - 16皮摩尔)[123I]IBZM后,大鼠脑内的摄取显示纹状体与小脑的比值从5分钟时的1.5增加到2小时时的6.9。嗅结节与小脑的比值也从1.6增加到3.3。测试的其他脑区未显示出统计学上的显著增强。在90分钟时进行测试,共同注射40纳摩尔S(-)IBZM、4微摩尔S(-)BZM或200纳摩尔氟哌啶醇可取代[123I]IBMZ。使用4微摩尔R(+)BZM仅导致轻微取代,表明体内和体外均存在取代的立体特异性。在黑质和脑桥 - 延髓也观察到了取代,但在海马或额叶和枕叶皮质未观察到。这些数据为使用[123I]IBZM进行SPECT分析在人类患者基底神经节中开展D2受体的体内结合研究提供了所需的背景。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验